← Human Trials & Peer-Reviewed Studies
Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness
Plain-language guide to PMID 10199772 (1999): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and TRH (Thyrotropin-Releasing Hormone).
Key Facts
- PMID
- 10199772
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Van den Berghe G et al. (8 authors)
- DOI
- 10.1210/jcem.84.4.5636
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and TRH (Thyrotropin-Releasing Hormone), published as a randomized controlled trial.
Protracted critical illness is marked by protein wasting resistant to feeding, by accumulation of fat stores, and by suppressed pulsatile release of GH and TSH.
Metabolic markers were independent of elevated serum cortisol.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
The design is described as randomized, placebo-controlled and crossover.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.
What Was Measured
The subject headings attached to it are Bone and Bones, Critical Illness, Human Growth Hormone, Insulin, Insulin-Like Growth Factor Binding Proteins, Leptin and Oligopeptides.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and TRH (Thyrotropin-Releasing Hormone).
The publication is from 1999 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the TRH (Thyrotropin-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
TRH (Thyrotropin-Releasing Hormone): A 3-amino-acid hypothalamic hormone (protirelin) that triggers TSH and prolactin release.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- TRH (Thyrotropin-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.